Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL - Episode 1

Epcoritamab Inducing Complete Responses in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

January 28, 2021

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Now Playing: Epcoritamab Inducing Complete Responses in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Now Playing
    EP. 1: Epcoritamab Inducing Complete Responses in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    EP. 1: Epcoritamab Inducing Complete Responses in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Martin Hutchings, MD, PhD, presents slides from the 62nd ASH Annual Meeting and Exposition for the phase 1/2 study for epcoritamab inducing complete responses in relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy.

    x